| Tarlatamab studied in …STUDIED_INderived35 of 35show fewer |
|---|
| → studied in | NCT07037758Phase 1 · recruiting A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) · 35 trials list this drug (30 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06814496Phase 1/Phase 2 · recruiting Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors · 35 trials list this drug (30 active) | — | — | Melanoma,Glioblastoma,Lung Non-Small Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07203053Phase 2 · recruiting A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 · 35 trials list this drug (30 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07061080Phase 2 · terminated Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab · 35 trials list this drug (30 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06816394Phase 2 · recruiting Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS) · 35 trials list this drug (30 active) | — | — | Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07778316Phase 3 · recruiting Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) · 35 trials list this drug (30 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07243470Phase 1/Phase 2 · recruiting Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors · 35 trials list this drug (30 active) | — | — | Adult Central Nervous System Neoplasm,Childhood Central Nervous System Neoplasm,Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05361395Phase 1 · active not recruiting First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) · 35 trials list this drug (30 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07016230Phase 2 · recruiting Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB) · 35 trials list this drug (30 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07005128Phase 3 · active not recruiting A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) · 35 trials list this drug (30 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07803848Phase 2 · recruiting Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status · 35 trials list this drug (30 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07111507Phase 2 · recruiting A Study of Tarlatamab for People With Prostate Cancer · 35 trials list this drug (30 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07788677Phase 1 · not yet recruiting Tarlatamab Treatment Before and After Surgery in Surgically Resectable Recurrent High-grade Glioma: a Window of Opportunity Study (TARLAGLIA Study) · 35 trials list this drug (30 active) | — | — | High-Grade Glioma, NOS | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07531095Phase 1 · recruiting Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · 35 trials list this drug (30 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06745323Phase 2 · active not recruiting A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC · 35 trials list this drug (30 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07402343Phase 2 · recruiting Tarlatamab for SCLC Brain Metastases · 35 trials list this drug (30 active) | — | — | Brain Neoplasm,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05060016Phase 2 · active not recruiting A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) · 35 trials list this drug (30 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06502977Phase 2 · active not recruiting Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment · 35 trials list this drug (30 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07242547Phase 2 · recruiting Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients · 35 trials list this drug (30 active) | — | — | Respiratory System Neoplasm,Thoracic Neoplasm,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07423585Phase 2 · recruiting Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer · 35 trials list this drug (30 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06598306Phase 1 · recruiting Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) · 35 trials list this drug (30 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07637513Phase 3 · not yet recruiting Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer · 35 trials list this drug (30 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06551142Phase 1 · recruiting A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) · 35 trials list this drug (30 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06898957Phase 1 · active not recruiting Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) · 35 trials list this drug (30 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06117774Phase 3 · active not recruiting Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) · 35 trials list this drug (30 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07328490Phase 1/Phase 2 · withdrawn Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer · 35 trials list this drug (30 active) | — | — | Extrapulmonary Neuroendocrine Carcinoma,Small Cell Neuroendocrine Carcinoma,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06893783Phase 2 · recruiting Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients · 35 trials list this drug (30 active) | — | — | Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06937905Phase 3 · recruiting Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) · 35 trials list this drug (30 active) | — | — | Neuroendocrine Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05740566Phase 3 · active not recruiting Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer · 35 trials list this drug (30 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06211036Phase 3 · active not recruiting Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab · 35 trials list this drug (30 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03319940Phase 1 · active not recruiting Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) · 35 trials list this drug (30 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04885998Phase 1 · completed AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) · 35 trials list this drug (30 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06776250Phase 2 · recruiting Study of How Safe and Effective Tarlatamab is in Brain Cancers · 35 trials list this drug (30 active) | — | — | Astrocytic Tumor,Oligodendroglial Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04702737Phase 1 · completed A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer · 35 trials list this drug (30 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06064500approved for marketing Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer · 35 trials list this drug (30 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |